Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 376 to 390 of 1688 results for carers

  1. Impact of enhanced developmental support and surveillance for children born preterm on parents and carers:- Does enhanced developmental support and surveillance improve outcomes for the parents and carers of children born preterm?

    born preterm on parents and carers:- Does enhanced developmental support and surveillance improve outcomes for the parents and...

    Research recommendation
    Published
    15 October 2018

  2. Chronic kidney disease: assessment and management (NG203)

    This guideline covers care and treatment for people with, or at risk of, chronic kidney disease (CKD). It aims to prevent or delay the progression, and reduce the risk of complications and cardiovascular disease. It also covers managing anaemia and hyperphosphataemia associated with CKD.

    NICE guideline
    Last updated
    24 November 2021
    View recommendations

    Sections for NG203

  3. Belantamab mafodotin with bortezomib and dexamethasone for treating relapsed or refractory multiple myeloma after 1 or more treatments ID6212

    In development [GID-TA11203] Expected publication date: 05 March 2025

    Technology appraisal guidance
    In development

  4. Lecanemab for treating mild cognitive impairment or mild dementia caused by Alzheimer's disease [ID4043]

    In development [GID-TA11220] Expected publication date: 05 February 2025

    Technology appraisal guidance
    In development

  5. Neonatal parenteral nutrition (NG154)

    This guideline covers parenteral nutrition (intravenous feeding) for babies born preterm, up to 28 days after their due birth date and babies born at term, up to 28 days after their birth. Parenteral nutrition is often needed by preterm babies, critically ill babies, and babies who need surgery.

    NICE guideline
    Published
    26 February 2020
    View recommendations

    Sections for NG154

  6. Patient support and information:- A descriptive study involving patients who have had neutropenic sepsis and their carers should be undertaken to find out what types of support and information patients and carers were given, which of these they found helpful or unhelpful, and whether they think additional or different types of support or information are needed.

    neutropenic sepsis and their carers should be undertaken to find out what types of support and information patients and...

    Research recommendation
    Published
    9 June 2015

  7. Sebelipase alfa for treating Wolman disease (HST30)

    Evidence-based recommendations on sebelipase alfa (Kanuma) for long-term enzyme replacement therapy in Wolman disease (rapidly progressive lysosomal acid lipase deficiency) in people aged 2 years and under when treatment starts.

    Highly specialised technologies guidance
    Published
    10 January 2024
    View recommendations

    Sections for HST30

  8. Continuous subcutaneous insulin infusion for the treatment of diabetes mellitus (TA151)

    Evidence-based recommendations on continuous subcutaneous insulin infusion (insulin pump therapy) for treating type 1 diabetes in adults and children.

    Technology appraisal guidance
    Published
    23 July 2008
    View recommendations

    Sections for TA151

  9. Who can register as a stakeholder?

    Find out more about the types of organisations that can register to be a stakeholder at NICE.

  10. Models of person-centred support:- What models of delivering person-centred support are effective and cost effective for people with a learning disability and behaviour that challenges, and their families and carers?What are the views and experiences of people with a learning disability and behaviour that challenges and their family members and carers, of different models of delivering person-centred support?

    and carers?What are the views and experiences of people with a learning disability and behaviour that challenges and their family...

    Research recommendation
    Published
    15 November 2018

  11. Cancer of the upper aerodigestive tract: assessment and management in people aged 16 and over (NG36)

    This guideline covers assessing and managing cancers of the upper aerodigestive tract in people aged 16 and over. These are cancers of the airways of the head and neck, including the mouth, throat, larynx (voicebox) and sinuses. It aims to reduce variation in practice and improve survival.

    NICE guideline
    Last updated
    6 June 2018
    View recommendations

    Sections for NG36

  12. Esketamine nasal spray for treatment-resistant depression (TA854)

    Evidence-based recommendations on esketamine (Spravato) for treatment-resistant depression in adults.

    Technology appraisal guidance
    Published
    14 December 2022
    View recommendations

    Sections for TA854

  13. Guidance on the use of electroconvulsive therapy (TA59)

    Evidence-based recommendations on electroconvulsive therapy (ECT) for treating catatonia, prolonged or severe manic episodes or schizophrenia in adults.

    Technology appraisal guidance
    Last updated
    1 October 2009
    View recommendations

    Sections for TA59

  14. Medical technologies evaluation programme process guide (PMG34)

    Medical technologies evaluation programme process guide

  15. Human growth hormone (somatropin) for the treatment of growth failure in children (TA188)

    Evidence-based recommendations on human growth hormone (somatropin; Genotropin, Humatrope, Norditropin, NutropinAq, Omnitrope, Saizen, Zomacton) for treating growth failure in children.

    Technology appraisal guidance
    Published
    26 May 2010
    View recommendations

    Sections for TA188